Immunologic Targeting of FOXP3 in Inflammatory Breast Cancer Cells

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Nair, Smita ^a   Aldrich, Amy J ^a   McDonnell, Eoin ^a   Cheng, Qing ^a   Aggarwal, Anshu ^a   Patel, Pujan ^a   Williams, Monique M ^a   Boczkowski, David ^a   Lyerly, H Kim ^a   Morse, Michael A ^a   Devi, Gayathri R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TRANSCRIPTION FACTOR FOXP3;

ANTIGEN PRESENTATION; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DENDRITIC CELL; EMBRYO; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATORY BREAST CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; T LYMPHOCYTE; TUMOR CELL DESTRUCTION; TUMOR IMMUNITY;

ANIMALS; ANTIGEN PRESENTATION; APOPTOSIS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INFLAMMATORY BREAST NEOPLASMS; LYMPHOCYTE ACTIVATION; MICE; PHENOTYPE; RECURRENCE; S-PHASE KINASE-ASSOCIATED PROTEINS; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

MURINAE; MUS;

EID: 84872289947     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053150     Document Type: Article

References (58)

1. Fontenot JD, Gavin MA, Rudensky AY, (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4: 330-336.
2. Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, et al. (2006) Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 212: 8-27.
3. Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, et al. (2002) Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 168: 4272-4276.
4. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, et al. (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9: 606-612.
5. Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, et al. (2004) Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173: 1444-1453.
6. Perez SA, Karamouzis MV, Skarlos DV, Ardavanis A, Sotiriadou NN, et al. (2007) CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients. Clin Cancer Res 13: 2714-2721.
7. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, et al. (2005) Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 65: 2457-2464.
8. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949.
9. Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, et al. (2006) Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 66: 3294-3302.
10. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, et al. (2001) Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61: 4766-4772.
11. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, et al. (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169: 2756-2761.
12. Martin F, Ladoire S, Mignot G, Apetoh L, Ghiringhelli F, (2010) Human FOXP3 and cancer. Oncogene 29: 4121-4129.
13. Hinz S, Pagerols-Raluy L, Oberg HH, Ammerpohl O, Grussel S, et al. (2007) Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 67: 8344-8350.
14. Morse MA, Secord AA, Blackwell K, Hobeika AC, Sinnathamby G, et al. (2011) MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer. Clin Cancer Res 17: 3408-3419.
15. Ladoire S, Arnould L, Apetoh L, Coudert B, Martin F, et al. (2008) Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res 14: 2413-2420.
16. Morse MA, Hobeika A, Serra D, Aird K, McKinney M, et al. (2012) Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function. Cancer Gene Ther 19: 30-37.
17. Ebert LM, Tan BS, Browning J, Svobodova S, Russell SE, et al. (2008) The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Res 68: 3001-3009.
18. Zuo T, Wang L, Morrison C, Chang X, Zhang H, et al. (2007) FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 129: 1275-1286.
19. Wang R, Kozhaya L, Mercer F, Khaitan A, Fujii H, et al. (2009) Expression of GARP selectively identifies activated human FOXP3+ regulatory T cells. Proc Natl Acad Sci U S A 106: 13439-13444.
20. Niu J, Jiang C, Li C, Liu L, Li K, et al. (2011) Foxp3 expression in melanoma cells as a possible mechanism of resistance to immune destruction. Cancer Immunol Immunother 60: 1109-1118.
21. Zuo T, Liu R, Zhang H, Chang X, Liu Y, et al. (2007) FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J Clin Invest 117: 3765-3773.
22. Liu R, Wang L, Chen G, Katoh H, Chen C, et al. (2009) FOXP3 up-regulates p21 expression by site-specific inhibition of histone deacetylase 2/histone deacetylase 4 association to the locus. Cancer Res 69: 2252-2259.
23. Grant C, Oh U, Fugo K, Takenouchi N, Griffith C, et al. (2006) Foxp3 represses retroviral transcription by targeting both NF-kappaB and CREB pathways. PLoS Pathog 2: e33.
24. Zhang M, Guo RX, Mo LQ, Liao XX, Li W, et al. (2009) Nuclear factor-kappaB mediates cytoprotection of hydrogen peroxide preconditioning against apoptosis induced by oxidative stress in PC12 cells. Clin Exp Pharmacol Physiol 36: 304-311.
25. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, et al. (2006) Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24: 5373-5380.
26. Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, et al. (2009) Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 69: 2000-2009.
27. Mansfield AS, Heikkila PS, Vaara AT, von Smitten KA, Vakkila JM, et al. (2009) Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer. BMC Cancer 9: 231.
28. Jaberipour M, Habibagahi M, Hosseini A, Habibabad SR, Talei A, et al. (2010) Increased CTLA-4 and FOXP3 transcripts in peripheral blood mononuclear cells of patients with breast cancer. Pathol Oncol Res 16: 547-551.
29. Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH, (2005) Epidemiology of inflammatory breast cancer (IBC). Breast Dis 22: 9-23.
30. Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, et al. (2010) Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin 60: 351-375.
31. Aird KM, Allensworth JL, Batinic-Haberle I, Lyerly HK, Dewhirst MW, et al. (2012) ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells. Breast Cancer Res Treat 132: 109-119.
32. Nair S, Boczkowski D, Fassnacht M, Pisetsky D, Gilboa E, (2007) Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res 67: 371-380.
33. Aird KM, Ghanayem RB, Peplinski S, Lyerly HK, Devi GR, (2010) X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor. Mol Cancer Ther 9: 1432-1442.
34. Aird KM, Ding X, Baras A, Wei J, Morse MA, et al. (2008) Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression. Mol Cancer Ther 7: 38-47.
35. Morse MA, Hobeika AC, Osada T, Serra D, Niedzwiecki D, et al. (2008) Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 112: 610-618.
36. Cheng Q, Chang JT, Geradts J, Neckers LM, Haystead T, et al. (2012) Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer. Breast Cancer Res 14: R62.
37. Nair S, Archer GE, Tedder TF (2012) Isolation and generation of human dendritic cells. Curr Protoc Immunol Chapter 7: Unit7 32.
38. Pruitt SK, Boczkowski D, de Rosa N, Haley NR, Morse MA, et al. (2011) Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. Eur J Immunol 41: 3553-3563.
39. Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, et al. (2000) Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 6: 1011-1017.
40. Nair S, Boczkowski D, Moeller B, Dewhirst M, Vieweg J, et al. (2003) Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 102: 964-971.
41. Karanikas V, Speletas M, Zamanakou M, Kalala F, Loules G, et al. (2008) Foxp3 expression in human cancer cells. J Transl Med 6: 19.
42. Fassnacht M, Lee J, Milazzo C, Boczkowski D, Su Z, et al. (2005) Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy. Clin Cancer Res 11: 5566-5571.
43. Mosca PJ, Hobeika AC, Clay TM, Nair SK, Thomas EK, et al. (2000) A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment. Blood 96: 3499-3504.
44. Allensworth JL, Aird KM, Aldrich AJ, Batinic-Haberle I, Devi GR (2012) XIAP Inhibition and Generation of Reactive Oxygen Species Enhances TRAIL Sensitivity in Inflammatory Breast Cancer Cells. Mol Cancer Ther.
45. Douglass S, Ali S, Meeson AP, Browell D, Kirby JA, (2012) The role of FOXP3 in the development and metastatic spread of breast cancer. Cancer Metastasis Rev 31: 843-854.
46. deLeeuw RJ, Kost SE, Kakal JA, Nelson BH, (2012) The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res 18: 3022-3029.
47. Drake CG, Jaffee E, Pardoll DM, (2006) Mechanisms of immune evasion by tumors. Adv Immunol 90: 51-81.
48. Mapara MY, Sykes M, (2004) Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 22: 1136-1151.
49. Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, et al. (2009) FOXP3 expression and overall survival in breast cancer. J Clin Oncol 27: 1746-1752.
50. Ladoire S, Arnould L, Mignot G, Coudert B, Rebe C, et al. (2011) Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 125: 65-72.
51. Myatt SS, Lam EW, (2007) The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer 7: 847-859.
52. Merkenschlager M, von Boehmer H, (2010) PI3 kinase signalling blocks Foxp3 expression by sequestering Foxo factors. J Exp Med 207: 1347-1350.
53. Igney FH, Krammer PH, (2002) Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2: 277-288.
54. Jazirehi AR, (2010) Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy. Anticancer Drugs 21: 805-813.
55. Varfolomeev E, Goncharov T, Maecker H, Zobel K, Komuves LG, et al. (2012) Cellular inhibitors of apoptosis are global regulators of NF-kappaB and MAPK activation by members of the TNF family of receptors. Sci Signal 5: ra22.
56. Dougan M, Dougan S, Slisz J, Firestone B, Vanneman M, et al. (2010) IAP inhibitors enhance co-stimulation to promote tumor immunity. J Exp Med 207: 2195-2206.
57. Hu D, Liu S, Shi L, Li C, Wu L, et al. (2010) Cleavage of survivin by Granzyme M triggers degradation of the survivin-X-linked inhibitor of apoptosis protein (XIAP) complex to free caspase activity leading to cytolysis of target tumor cells. J Biol Chem 285: 18326-18335.
58. Seeger JM, Brinkmann K, Yazdanpanah B, Haubert D, Pongratz C, et al. (2010) Elevated XIAP expression alone does not confer chemoresistance. Br J Cancer 102: 1717-1723.